Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Health and Drug Alerts

CYPHER coronary stents and risk of thrombosis

Stephen B. Choi
CMAJ August 05, 2003 169 (3) 218;
Stephen B. Choi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: The use of coronary stents has improved the results of percutaneous coronary revascularization procedures. Along with newer antithrombotic therapy using glycoprotein IIb/IIIa platelet inhibitors, stents are used frequently in the management of acute coronary syndromes.1,2,3 However, a persistent problem with stents is the subsequent development of in-stent stenosis. Data from the British Columbia Cardiac Registries during the mid-1990s show that restenosis occurs in about 15% of patients with stents.1 To prevent this, stents have now been developed that are coated with drugs believed to be helpful in maintaining stent patency. Initial clinical trials of these drug-eluting stents have been completed and other trials are underway.

The CYPHER stent, a metal device that is coated with sirolimus, was approved in April 2003 by the US Food and Drug Administration (FDA) for use in angioplasty procedures. Early experience with the CYPHER stent has shown that stent thrombosis occurs in 0.5% of patients.4 The stent's manufacturer, Cordis Corporation, and the US Food and Drug Administration (FDA) estimate that the device has now been used in over 50 000 patients. The device was recently licensed for use in Canada.

Since the product was approved in the United States, the FDA has received 47 reports of stent thrombosis that occurred at the time of implantation or within a few days of implantation.5 Although it is unclear whether the rate of stent thrombosis that is being detected in clinical practice is higher than that observed in the pre-approval clinical trials, the manufacturer issued a warning letter to US physicians on July 7.6

The device: The stent, which is made of stainless steel, is inserted percutaneously and implanted in a diseased segment of a coronary artery. It is then expanded to fit snugly against the vessel wall.1 However, its metallic surface can stimulate thrombosis before it becomes entirely covered with endothelial tissue (a process that may take several weeks). During this time (and for 3 months after insertion), patients continue to take antiplatelet therapy. Sirolimus is an immunosupressant agent that is believed to prevent restenosis, probably by inhibition of cytokine-mediated and growth-factor-mediated proliferation of lymphocytes and smooth-muscle cells. A fixed amount of sirolimus per unit area is applied to the CYPHER stent, which is designed to release about 80% of the drug within 30 days of implantation.

In its letter to physicians, the manufacturer notes that some cardiologists may be inappropriately inserting the stents, mainly by overexpanding narrower stents so that they will fit in arteries with larger diameters. The manufacturer reports that because of high demand for the stent it focused its production on the smaller stents but is now producing a larger stent. The manufacturer also notes that some in-vitro laboratory experiments show that sirolimus potentiates the effect of some platelet agonists and thus may promote thrombus formation. Furthermore, it should be noted that in 1 major study that demonstrated the benefits of the CYPHER stent7 the device was investigated in a limited clinical application. Patients were eligible if they had disease of a native coronary artery (i.e., those with diseased grafts were excluded) in the setting of stable or unstable angina, or silent ischemia. Importantly, acute myocardial infarction was one of numerous exclusion criteria.

It is unclear whether the failures that have been reported are the result of inappropriate use of the stent as the manufacturer suggests. The FDA and the manufacturer are investigating and ask physicians to report stent failures.

What to do: The FDA recommends that health care professionals:

1. Match the stent size as closely as possible to vessel diameter.

2. Use stents in previously untreated vessels only. The stent is not indicated for the treatment of restenosis.

3. Use an adequate antiplatelet regimen.

4. Use proper technique to ensure that the stent is fully deployed and in contact with the vessel wall.

Stephen B. Choi Editorial Fellow CMAJ

Footnotes

  • Published at www.cmaj.ca on July 11, 2003.

    Acknowledgements: I thank Drs. Madhu Natarajan and William Ghali for their critical review of a draft of this report.

References

  1. 1.↵
    Buller CE, Carere RG. New advances in the management of acute coronary syndromes: 3. The role of catheter-based procedures. CMAJ 2002;166(1):51-61.
    OpenUrlFREE Full Text
  2. 2.↵
    Natarajan MK, Yusuf S. Primary angioplasty for ST-segment elevation myocardial infarction: Ready for prime time? CMAJ 2003;169(1):32-5.
    OpenUrlFREE Full Text
  3. 3.↵
    Ghali WA, Donaldson CR, Knudtson ML, Lewis SJ, Maxwell CJ, Tu JV. Rising to the challenge: transforming the treatment of ST-segment elevation myocardial infarction. CMAJ 2003;169(1):35-7.
    OpenUrlFREE Full Text
  4. 4.↵
    Lemos PA, Lee C, Degertekin M, Saia F, Tanabe K, Arampatzis CA, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes. Insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2003;41(11):2093-9.
    OpenUrlCrossRefPubMed
  5. 5.↵
    US Food and Drug Administration. Cordis Corporation issues a health care professional letter regarding the CYPHER stent. FDA News 2003 July 8. Available: www.fda.gov/bbs/topics/NEWS/2003/NEW00919.html (accessed 2003 July 11).
  6. 6.↵
    Cordis Corporation. Subacute thrombosis in association with CYPHER coronary stents — What is known? [letter to US physicians]. 2003 July 7. Available: www.fda.gov/bbs/topics/NEWS/2003/NEW00919.html (accessed 2003 July 11).
  7. 7.↵
    Morice MC, Serruys PW, Sousa JE, Fajadet J, Ben Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346(23):1773-80.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (3)
CMAJ
Vol. 169, Issue 3
5 Aug 2003
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
CYPHER coronary stents and risk of thrombosis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CYPHER coronary stents and risk of thrombosis
Stephen B. Choi
CMAJ Aug 2003, 169 (3) 218;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
CYPHER coronary stents and risk of thrombosis
Stephen B. Choi
CMAJ Aug 2003, 169 (3) 218;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Coronary artery stents: identification and evaluation
  • Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF
  • Google Scholar

More in this TOC Section

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Cardiovascular medicine

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire